Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Risedronate Clear all
Completed Phase 3 Interventional

Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer

NCT00054418
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
calcium carbonate, vitamin D, risedronate sodium, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
198
States / cities
Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 124 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 4 Interventional

OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women

NCT00130403
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
risedronate sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 4 Interventional

Risedronate in the Prevention of Osteoporosis in Postmenopausal Women

NCT00402441
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Risedronate (HMR4003)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
45 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Not applicable Interventional Results available

IGF-1 and Bone Loss in Women With Anorexia Nervosa

NCT01406444
View directory record Official record
Conditions
Anorexia Nervosa, Osteopenia, Osteoporosis
Interventions
rhIGF-1, Risedronate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose

NCT00577850
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
risedronate, alendronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Gainesville, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Results available

Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use

NCT00221299
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate, Parathyroid Hormone
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 4 Interventional

Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer

NCT00082277
View directory record Official record
Conditions
Breast Cancer
Interventions
Anastrozole, Risedronate Sodium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years and older · Female only
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Palm Springs, California • Jacksonville, Florida • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 4 Interventional

Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy

NCT00616694
View directory record Official record
Conditions
Osteoporosis
Interventions
Actonel
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 85 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 21, 2008 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Not applicable Interventional

Rise & Renew: Supporting Well-Being in Black Women After the Loss of a Loved One

NCT07009795
View directory record Official record
Conditions
Bereavement, Grief, Psychological Distress, Well Being
Interventions
Rise & Renew Hybrid Grief Support Program
Behavioral
Lead sponsor
Lillian Haley, PhD
Industry
Eligibility
40 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lithonia, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 18, 2026, 2:40 PM EDT
Terminated Phase 4 Interventional Results available

Bone Microarchitecture in Osteopenic Postmenopausal Women

NCT00577395
View directory record Official record
Conditions
Osteoporosis
Interventions
placebo, risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 57 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Tuscon, Arizona • Omaha, Nebraska • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

NCT00918749
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
150 mg, 75 mg, 100 mg
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
6
States / cities
Daytona Beach, Florida • Fort Myers, Florida • Honolulu, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 18, 2026, 2:40 PM EDT
Completed No phase listed Observational

Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate

NCT00837746
View directory record Official record
Conditions
Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
7
States / cities
Palm Desert, California • Lakewood, Colorado • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food

NCT00868907
View directory record Official record
Conditions
Healthy
Interventions
35 mg risedronate DR tablet
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
4
States / cities
Gainesville, Florida • Miami, Florida • Honolulu, Hawaii + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis

NCT01611571
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate, Teriparatide, Placebo Teriparatide, placebo Risedronate
Drug
Lead sponsor
Columbia University
Other
Eligibility
30 Years to 85 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Not applicable Interventional

Prevention of Osteoporosis in Breast Cancer Survivors

NCT00567606
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Strength/Weight Training & Drug/Supplement, Drug/Supplement only
Other · Combination Product
Lead sponsor
University of Nebraska
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Kearney, Nebraska • Lincoln, Nebraska • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children

NCT00106028
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
risedronate sodium (Actonel), Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
4 Years to 15 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
5
States / cities
Miami, Florida • Omaha, Nebraska • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.

NCT00266708
View directory record Official record
Conditions
Renal Transplant Osteodystrophy
Interventions
Risedronate, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Results available

Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer

NCT00859027
View directory record Official record
Conditions
Prostate Cancer
Interventions
risedronate, Placebo risedronate oral tablet
Drug
Lead sponsor
UConn Health
Other
Eligibility
55 Years to 85 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Results available

VERtebral Fracture Treatment Comparisons in Osteoporotic Women

NCT01709110
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Teriparatide, Risedronate, Placebo, Calcium, Vitamin D
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Female only
Enrollment
1,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
30
States / cities
Birmingham, Alabama • Concord, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Not applicable Interventional

The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)

NCT00118508
View directory record Official record
Conditions
Osteoporosis
Interventions
risedronate (including placebo)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids

NCT01575873
View directory record Official record
Conditions
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Interventions
Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Sacramento, California • Lakewood, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Results available

Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy

NCT00485953
View directory record Official record
Conditions
Bone Loss, Osteoporosis, Breast Cancer
Interventions
risedronate
Drug
Lead sponsor
Susan L. Greenspan
Other
Eligibility
55 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD

NCT00577837
View directory record Official record
Conditions
Postmenopausal
Interventions
risedronate, experimental
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
4
States / cities
Daytona Beach, Florida • Gainesville, Florida • Shawnee Mission, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Weight Loss With Risedronate for Bone Health

NCT03411902
View directory record Official record
Conditions
Bariatric Surgery Candidate, Bone Loss, Weight Loss
Interventions
Risedronate Sodium 150 MG, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 18, 2026, 2:40 PM EDT